Viropharma Biologics LLC
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 2 name spellings.
4
Ending by 2030
Aug 2028
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 9, 2026The maintenance fee for Corticosteroid Compositions (US 9,050,368) comes due Dec 9, 2026. Unpaid by Jun 9, 2027, it lapses early.
Recent changes
- 2 terms have ended since Aug 18, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,782,347 | Topical Corticosteroids for the Treatment of Inflammatory Diseases of the Gastrointestinal Tract In force · High confidence | In force | High confidence | |
| US 11,357,859 | Compositions for the Treatment of Gastrointestinal Inflammation In force · Medium confidence | In force | Medium confidence | |
| US 10,293,052 | Compositions for the Treatment of Gastrointestinal Inflammation In force · High confidence | In force | High confidence | |
| US 9,050,368 | Corticosteroid Compositions In force · High confidence | In force | High confidence | |
| US 8,865,692 | Compositions for the Treatment of Gastrointestinal Inflammation In force · High confidence | In force | High confidence | |
| US 9,616,111 | C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency In force · High confidence | In force | High confidence | |
| US 10,080,788 | C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency In force · High confidence | In force | High confidence | |
| US 10,105,423 | C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency In force · High confidence | In force | High confidence | |
| US 10,130,690 | C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency In force · High confidence | In force | High confidence | |
| US 10,201,595 | C1-INH Compositions and Methods for the Prevention and Treatment of Disorders Associated with C1 Esterase Inhibitor Deficiency In force · High confidence | In force | High confidence |
Also on record, not counted in the 15: 2 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
1 abandoned · 3 no status recorded